Press

Built by sites, validated by industry: the next chapter of the Digital Innovation Initiative begins this week.   The Society for Clinical Research Sites (SCRS), the premier global advocacy organization for the clinical research site community, today announced the AI guidance framework working group, the next chapter of its Digital Innovation Initiative (DII). The group will work to create the framework that will give sites a practical, independent foundation for adopting artificial intelligence safely and effectively, and give sponsors and CROs a credible benchmark for what good looks like at the site level.  AI is already reshaping site operations, from patient identification and documentation to data entry and communication. Yet sites have had no independent, site-specific guidance to inform their adoption decisions. The result is a lot of noise and very little clarity. This framework is designed to close that gap.  A working group of 12–15 site professionals will build the framework from operational reality, drawing on the day-to-day experience of the people who run trials. Members represent a range of roles and organization sizes, with adjacent AI practitioners contributing additional perspectives. The working group begins its work this week.  The process is designed to reflect the wider community, not only the working group:  Community survey – In November, SCRS will invite sites across our community to share how they are using, evaluating, or avoiding AI today.  Practitioner input – Case examples from practitioners already applying AI in site settings will ground the guidance in practice.  Industry review – In spring 2027, sponsor and CRO partners will review the completed draft to stress-test and validate it, without co-authoring it. The framework stays site-built and gains industry confidence.  “Sites are being asked to make AI decisions now, often without a trusted reference point,” said Jimmy Bechtel, Chief Site Success Officer at SCRS. “This framework starts with the people doing the work. Sites define what safe and effective looks like in practice, and industry helps pressure-test it. The goal is clarity the whole field can move forward on together.”  For sponsors and CROs, a shared, site-grounded standard supports more consistent expectations, smoother collaboration, and stronger trial execution. For sites, it offers a way to evaluate AI with confidence, on their own terms.  The completed framework will provide practical guidance on the safe and effective use of AI in clinical research site operations. It will be published as a living resource on the SCRS website so it can evolve alongside technology and the regulatory landscape. SCRS guidance is intended to support decision-making and does not constitute regulatory or legal advice, vendor endorsement, or certification.    About the Society for Clinical Research Sites (SCRS) The Society for Clinical Research Sites (SCRS) is the leading advocacy organization dedicated to unifying the voice of the global clinical research site community. Representing more than 12,000 research sites globally, SCRS facilitates industry collaborations and conversations dedicated to site-focused advocacy, education, mentorship, and connection. SCRS is an active and influential champion for sites in industry initiatives to ensure that the perspective of sites is heard and valued. Our Voice. Our Community. Your Success. Learn more at myscrs.org.

Bayer and Medpace earn top honors for operational excellence and dedication to clinical research site sustainability. October 27, 2026 – The Society for Clinical Research Sites (SCRS) has proudly named the recipients of the 2026 SCRS Eagle Award: Bayer in the sponsor category and Medpace in the Contract Research Organization (CRO) category. For more than ten years, the SCRS Eagle Award has set the industry standard for evaluating site-industry collaboration. Presented during the annual SCRS Global Site Solutions Summit Eagle Award Gala, sponsored by Advarra, this distinguished award honors industry organizations showing outstanding commitment to advancing clinical research through strong site partnerships. This year, global research sites scored organizations on eight key operational dimensions that drive daily trial execution and sustainability. The selection process is built entirely on direct, objective feedback from clinical research sites evaluating active study partnerships. Ultimately, Bayer and Medpace achieved the highest overall scores across all categories. Recipients were chosen from a highly competitive pool of finalists, including Johnson & Johnson, Merck/MSD, Novo Nordisk, and Sanofi in the sponsor category, alongside IQVIA, Novotech, Parexel, and Worldwide Clinical Trials in the CRO category. “We are deeply honored to receive the SCRS Eagle Award,” shared Dr. Christoph Koenen, Chief Medical Officer and Head of Clinical Development at Bayer. “This recognition is especially meaningful because it comes directly from the clinical trial sites and professionals who partner with us every day. Their trust, feedback and collaboration are essential to how we advance clinical research for patients. We remain committed to listening to our site partners, learning from their experiences, and acting on their feedback. Together, we will continue working to reduce administrative burden, improve efficiency and enhance experiences for sites, study participants, and patients.” “We are honored to be recognized as the 2026 SCRS Eagle Award winner,” said Gina Leisring, Sr. Vice President – Clinical Monitoring, Medpace. “Earning this distinction for a second consecutive year underscores our commitment to fostering strong, collaborative relationships with sites and reflects the trust our site partners place in us. We look forward to building on this momentum as we continue working together to accelerate the development of safe and effective therapies.” “The SCRS Eagle Award places objective site feedback at the center of improving cross-industry collaboration, added Sean Soth, Senior Vice President of Global Business Partnerships with SCRS. “Bayer and Medpace have demonstrated a profound commitment to empowering sites, building trust, and streamlining trial operations. On behalf of SCRS and the global research site community, we congratulate both organizations for their extraordinary efforts to elevate site partnerships.” An executive summary of the 2026 Eagle Award results will be distributed to all SCRS members and Global Impact Partners. Sponsors and CROs will also be able to invest in deeper site intelligence reports developed by SCRS to understand how their organization compares against peer groups. Learn more about the Eagle Award and industry insights at sitesolutionssummit.com/eagle-award. About Bayer Bayer is a global enterprise with core competencies in the life science fields of health care and nutrition. In line with its mission, “Health for all, Hunger for none,” the company’s products and services are designed to support efforts to master major challenges presented by a growing and aging global population and create value through innovation and growth. The Bayer brand stands for trust, reliability and quality throughout the world. In fiscal 2025, the Group employed around 88,000 people and had sales of 45.6 billion euros. R&D expenses amounted to 5.8 billion euros. For more information, go to bayer.com. About Medpace Medpace is a scientifically-driven, global, full-service clinical contract research organization (CRO) providing Phase I-IV clinical development services to the biotechnology, pharmaceutical and medical device industries. Medpace’s mission is to accelerate the global development of safe and effective medical therapeutics through its high-science and disciplined operating approach that leverages regulatory and therapeutic expertise across all major areas including oncology, cardiology, metabolic disease, endocrinology, central nervous system and anti-viral and anti-infective. Learn more at medpace.com. About the Society for Clinical Research Sites (SCRS) The Society for Clinical Research Sites (SCRS) is the leading advocacy organization dedicated to unifying the voice of the global clinical research site community. Representing more than 12,000 research sites globally, SCRS facilitates industry collaborations and conversations dedicated to site-focused advocacy, education, mentorship, and connection. SCRS is an active and influential champion for sites in industry initiatives to ensure that the perspective of sites is heard and valued. Our Voice. Our Community. Your Success. Learn more at myscrs.org.

October 22, 2026 – The Society for Clinical Research Sites (SCRS) is proud to announce Jennifer Byrne, Founder & CEO of Javara, as the recipient of the 2026 Christine K. Pierre Site Impact Award. Created in honor of late SCRS founder Christine K. Pierre, this award celebrates an industry leader who has made extraordinary contributions to amplifying the voice and advocating for the clinical research site community. Byrne was selected for her transformative vision and career-long dedication to strengthening site infrastructure and expanding research access. Throughout her 39-year career, Byrne has challenged traditional research models by embedding clinical trials directly within healthcare systems. Through Javara, she puts this vision into practice, equipping community sites with the sustainable infrastructure and partnerships needed to thrive. “This recognition is tremendously meaningful because it reflects the collective work of so many people who believe that every patient should have the opportunity to participate in research,” Byrne shared. “Receiving the Christine K. Pierre Site Impact Award validates the importance of our continued commitment to building a future where clinical research is more accessible, more trusted, and more connected to the communities we serve.” Under her leadership, Javara has served as an SCRS Global Impact Partner since 2022, and Byrne was recently invited to become a core member of SCRS’ new Public Policy committee. She actively advances the Society’s mission through industry meetings, publications and webinars, consistently sharing practical solutions to strengthen the broader site community. “Jennifer Byrne embodies the mission and legacy of Christine K. Pierre through her relentless advocacy for the clinical research site community,” said Allyson Small, Chief Operating Officer of SCRS. “From her foundational work as an SCRS Global Impact Partner to contributing to SCRS events and committees, Jennifer consistently elevates the voice of sites in conversations that shape our industry. She has dedicated her career to ensuring sites are valued, proving that investing in sites is the key to expanding research access and ensuring long-term sustainability.” The award was presented at the 2026 Global Site Solutions Summit in Orlando, Florida. Award nominations were open to any individuals employed by an SCRS member research site. For more information on the Christine K. Pierre Site Impact Award, visit the Global Site Solutions Summit website at sitesolutionssummit.com. About The Society for Clinical Research Sites (SCRS) The Society for Clinical Research Sites (SCRS) is the leading advocacy organization dedicated to unifying the voice of the global clinical research site community. Representing more than 12,000 research site members globally, SCRS facilitates industry collaborations and conversations dedicated to site-focused advocacy, education, mentorship, and connection. SCRS is an active and influential champion for sites in industry initiatives to ensure that the perspective of sites is heard and valued. Learn more and get involved at myscrs.org. Our voice. Our community. Your Success.

September 3, 2026 – The Society for Clinical Research Sites (SCRS) today announced the finalists for the 2026 Eagle Award, the clinical research industry’s leading tool for evaluating and improving how sponsors and CROs partner with research sites.  Sponsor finalists: Bayer, Johnson & Johnson Innovative Medicine, Merck/MSD, Novo Nordisk, Sanofi  CRO finalists: IQVIA, Medpace, Novotech, Parexel, Worldwide Clinical Trials  For more than a decade, the Eagle Award has been built on feedback directly from clinical research sites across the globe. Each year, sites score their sponsor and CRO partners across key categories, including business development, budgeting, contracts, payments, communication, study startup, and more.   New in 2026, site feedback is aligned to active study relationships in the past year and linked to specific therapeutic areas and site types. Each evaluation category includes qualitative feedback, giving sponsors and CROs context behind their scores. This gives the industry its most objective view of what is working well and opportunities for improvement within site-industry relationships.  “The SCRS Eagle Award places objective site feedback at the center of improving cross-industry collaboration. The output is different than internal feedback loops or even NPS findings.   Sites scored across the dimensions that define practical study performance and support the industry’s collective success,” said Sean Soth, Senior Vice President of Global Business Partnerships with SCRS.  “SCRS congratulates this year’s finalists for their continued commitment to site success and looks forward to celebrating the recipients.” One sponsor and one CRO that consistently earn top marks across all categories will be named the 2026 Eagle Award recipients. An executive summary of the results will be distributed to all SCRS site members and Global Impact Partners. Sponsors and CROs will also have the option to invest in deeper site intelligence reports, covering areas of exceptionality, areas of need, and how their organization compares to peer groups.  The 2026 Eagle Award recipients will be announced on October 17, 2026 at the Eagle Award Gala & Awards Ceremony, sponsored by Advarra, at the SCRS Global Site Solutions Summit in Orlando, Florida.   About the Society for Clinical Research Sites (SCRS)  The Society for Clinical Research Sites (SCRS) is the leading advocacy organization dedicated to unifying the voice of the global clinical research site community. Representing more than 12,000 site members globally, SCRS facilitates industry collaborations and conversations dedicated to site-focused advocacy, education, mentorship, and connection. SCRS is an active and influential champion for sites in industry initiatives to ensure that the perspective of sites is heard and valued. Learn more and get involved at myscrs.org/. 

The Society for Clinical Research Sites (SCRS) congratulates David Vulcano on his appointment as CEO of the Association of Clinical Research Professionals (ACRP).  At the invitation of SCRS Founder Christine Pierre, David joined the SCRS Leadership Council in 2015 and has served as Honorary President since 2021.

October 13, 2025 – The Society for Clinical Research Sites (SCRS) proudly announces the 2025 recipients of the prestigious SCRS Eagle Award: Merck (known as MSD outside the United States and Canada) in the sponsor category and Medpace in the CRO category. Now in its 16th year, the SCRS Eagle Award celebrates outstanding collaborations between clinical research sites and their sponsor and CRO partners. Proudly sponsored by Advarra, this distinguished recognition highlights organizations that demonstrate leadership, professionalism, integrity, passion, and commitment to enhancing clinical research through meaningful site partnerships. Research sites globally participated in the annual SCRS Eagle Award survey to evaluate sponsor and CRO partners who consistently demonstrate excellence across multiple operational areas. This year’s comprehensive voting process engaged nearly 2,000 sites, who assessed over 16,300 active data points based on their experience working together over the past 12 months. Through the survey, nominees were scored across key operational categories including business development, budgeting approach, contract language, payment process, communication, efficient start-up, support for research participants from all communities, and effective use of technology. The recipient sponsor and CRO were selected based on their overall performance rankings from this extensive community assessment. Merck team accepting the 2025 Eagle Award   Jennifer Sheller, Senior Vice President and Head, Global Clinical Trial Operations at Merck shared, “Our company is deeply honored to receive the Eagle Award, a reflection of the invaluable partnership we share with clinical trial sites around the world. Sites are the heartbeat of clinical research. Their dedication, resilience and unwavering focus on patients make progress possible. We remain committed to empowering sites to focus on what truly matters: the rights, safety and well-being of every participant. By prioritizing critical to quality factors and removing unnecessary complexity, we aim to make research more agile, inclusive and impactful. Together, we are not just running trials – we are delivering hope through collaboration, urgency and purpose to turn scientific discovery into life-changing medicines and vaccines for patients and caregivers around the world.”   Medpace team accepting the 2025 Eagle Award “Medpace is thrilled to receive the 2025 Eagle Award”, said Gina Leisring, Sr. Vice-President, Clinical Monitoring at Medpace. “This recognition reflects our commitment to building exceptional partnerships with sites around the world. We would like to express our gratitude to the sites who play an essential role in effective clinical development, helping us bring new and innovative therapies to patients in need.” Sean Soth, SVP of Global Business Partnerships with SCRS added, “SCRS congratulates Merck and Medpace as the 2025 Eagle Award recipients, a recognition that comes directly from the global site community. Nearly 2,000 sites shared 16,300+ real-world data points about their experiences, and these organizations scored well across all categories within the SCRS Eagle Award survey. In an industry where collaboration is a critical success factor for patient outcomes, Merck and Medpace have proven that exceptional site partnerships aren’t just good business, they’re essential for advancing clinical research that changes lives. Congratulations to both organizations for outstanding efforts to elevate site collaboration.” Both awards were presented during the 2025 SCRS Global Site Solutions Summit Eagle Award Gala, sponsored by Advarra. Additional information about the SCRS Global Site Solutions Summit and Eagle Award can be found at sitesolutionssummit.com/global.   About Merck At Merck, known as MSD outside of the United States and Canada, we are unified around our purpose: We use the power of leading-edge science to save and improve lives around the world. For more than 130 years, we have brought hope to humanity through the development of important medicines and vaccines. We aspire to be the premier research-intensive biopharmaceutical company in the world – and today, we are at the forefront of research to deliver innovative health solutions that advance the prevention and treatment of diseases in people and animals. We foster a diverse and inclusive global workforce and operate responsibly every day to enable a safe, sustainable and healthy future for all people and communities. For more information, visit www.merck.com and connect with us on X (formerly Twitter), Facebook, Instagram, YouTube and LinkedIn. About Medpace Medpace is a scientifically-driven, global, full-service clinical contract research organization (CRO) providing Phase I-IV clinical development services to the biotechnology, pharmaceutical and medical device industries. Medpace’s mission is to accelerate the global development of safe and effective medical therapeutics through its high-science and disciplined operating approach that leverages regulatory and therapeutic expertise across all major areas including oncology, cardiology, metabolic disease, endocrinology, central nervous system and anti-viral and anti-infective. Headquartered in Cincinnati, Ohio, Medpace employs approximately 6,000 people across 44 countries as of June 30, 2025. Learn more at medpace.com. About the Society for Clinical Research Sites (SCRS) The Society for Clinical Research Sites (SCRS) is the leading advocacy organization dedicated to unifying the voice of the global clinical research site community. Representing more than 12,000 research sites in 50+ countries, SCRS facilitates industry collaborations and conversations dedicated to site-focused advocacy, education, mentorship, and connection. SCRS is an active and influential champion for sites in industry initiatives to ensure that the perspective of sites is heard and valued. Learn more and get involved at myscrs-new.local/. Our voice. Our community. Your success.  

October 9, 2025 – Mohammad Millwala, Founder and CEO of DM Clinical Research, has been recognized with the Christine K. Pierre Site Impact Award at the Global Site Solutions Summit, honoring his extraordinary impact within the clinical research site community and dedication to advancing site sustainability and growth. For nearly two decades, Millwala has embodied the mission and values championed by Christine K. Pierre, with an unwavering commitment to amplifying the voice of clinical research sites, particularly those serving historically underserved populations. Under his leadership, DM Clinical Research has grown from a single site in Houston to one of the largest independently owned site networks in the United States, with over 30 locations strategically placed in diverse communities across cities including New York, Chicago, Detroit, and Seattle. “Receiving the Christine K. Pierre Site Impact Award is a tremendous honor, but it truly belongs to our entire DM Clinical Research team,” said Millwala. “This recognition reflects our shared passion, dedication, and commitment to advancing clinical research and making a real difference in patients’ lives. Advancing site excellence means ensuring every patient has access to the future of medicine, and that’s what drives us every day.” Allyson Small, Chief Operating Officer with SCRS added, “Mohammad exemplifies the transformational leadership that Christine K. Pierre championed. As an SCRS Leadership Council member, active contributor to our IncluDE program, and the first site to join our Global Impact Partner program, he is a trusted advocate for sites worldwide. His work embodies Christine’s belief that clinical research succeeds only when every site has a voice at the table. From mentoring emerging sites to sharing his expertise through SCRS events, Mohammad carries Christine’s mission forward with dedication and heart. Christine would be proud to see how he continues to honor her vision and ensure her legacy thrives for generations to come.” Award nominations were open to any individuals employed by an SCRS member research site. For more information on the Christine K. Pierre Site Impact Award, visit the Global Site Solutions Summit website at sitesolutionssummit.com.   About the Society for Clinical Research Sites (SCRS) The Society for Clinical Research Sites (SCRS) is the leading advocacy organization dedicated to unifying the voice of the global clinical research site community. Representing more than 12,000 research sites in 50+ countries, SCRS facilitates industry collaborations and conversations dedicated to site-focused advocacy, education, mentorship, and connection. SCRS is an active and influential champion for sites in industry initiatives to ensure that the perspective of sites is heard and valued. Learn more and get involved at myscrs-new.local/. Our voice. Our community. Your success.

July 22, 2025 – The Society for Clinical Research Sites (SCRS) is proud to announce Monroe Biomedical Research (MBR) as a new Global Impact Partner (GIP). Located in Monroe, North Carolina, MBR conducts a broad range of outpatient and inpatient clinical trials, with a focus on infectious disease, internal medicine, cardiometabolic conditions, and respiratory diseases. MBR has distinguished itself as a research leader through consistent high enrollment performance and its ongoing efforts to advance representation in clinical trials, with an ethnically diverse, pre-screened patient database. As a GIP, MBR will work alongside SCRS and leading industry organizations to shape clinical research best practices and champion the voice of the clinical research site globally. “Becoming an SCRS Global Impact Partner is a meaningful milestone for Monroe Biomedical Research. As a company built on the belief that clinical trials should reflect and serve real-world communities, we’re excited to collaborate with SCRS and fellow leaders to strengthen the voice of sites, improve trial quality, accelerate enrollment, and ultimately improve outcomes for patients everywhere,” said Suvi Gross, CEO, Monroe Biomedical Research. Marcus Maleck, VP of Global Business Partnerships with SCRS, commented, “Monroe Biomedical Research’s status as one of the highest enrolling research centers in the U.S. brings tremendous value to the SCRS community. Their deep expertise and commitment to advancing inclusive clinical research will strengthen the collaborative efforts of our GIP program. We are proud to welcome MBR and look forward to the meaningful contributions they will make alongside our industry partners.” The SCRS GIP program fosters a unique collaboration between industry leaders and research sites, facilitating open dialogue and joint efforts to develop solutions to shared challenges across the clinical research landscape. For more information about the SCRS Global Impact Partner program, visit scrsprograms.com. About Monroe Biomedical Research (MBR)Monroe Biomedical Research is a world-class clinical research center based in Monroe, North Carolina. MBR conducts Phase I–IV clinical trials and is nationally recognized for its high enrollment rates and commitment to diverse patient participation. Since 2014, MBR has built a robust infrastructure supporting trials in asthma, COPD, diabetes, heart failure, internal medicine, and infectious diseases including COVID-19. About the Society for Clinical Research Sites (SCRS)  The Society for Clinical Research Sites (SCRS) is the leading advocacy organization dedicated to unifying the voice of the global clinical research site community. Representing more than 11,000 research sites in 50+ countries, SCRS facilitates industry collaborations and conversations dedicated to site-focused advocacy, education, mentorship, and connection. SCRS is an active and influential champion for sites in industry initiatives to ensure that the perspective of sites is heard and valued. Learn more and get involved at myscrs-new.local/.  Our voice. Our community. Your success.  

May 29, 2025 – Hawthorne Health, a leading community site network with more than 75 site locations across the United States, today announced its partnership with the Society for Clinical Research Sites (SCRS) as a Global Impact Partner. The SCRS Global Impact Partner (GIP) program establishes a unique collaboration between industry organizations and clinical research sites, creating dialogue and opportunities to develop innovative solutions that address mutual challenges in clinical research. As part of this strategic collaboration, Hawthorne Health will contribute to SCRS initiatives aimed at advancing site best practices for accessible clinical research. Hawthorne Health is deeply rooted in patient communities, with a nationwide network of 75+ community-based sites, including historically underserved and hard-to-reach areas. As a leading community site network, Hawthorne Health increases patient access, improves retention, and lowers study costs by seamlessly integrating trials into the fabric of patients’ everyday lives. “Our partnership with SCRS underscores Hawthorne Health’s dedication to enhancing accessibility and efficiency in clinical research,” said Josh Rose, CEO of Hawthorne Health. “Collaborating with SCRS enables us to advance awareness and adoption of community site models, reinforcing our commitment to improving access and representation in clinical research.” By integrating research into the communities where patients live, work, and receive care, Hawthorne Health reduces barriers to their participation, increasing accessibility, and fostering greater transparency and confidence in clinical trials. Hawthorne’s network mirrors the diverse populations it serves, bringing trials closer to those who need them most, and enabling sponsors to achieve recruitment goals faster and more effectively. “SCRS is honored to welcome Hawthorne Health to our distinguished group of Global Impact Partners,” said Marcus Maleck, Vice President of Global Business Partnerships with SCRS. “Their collaborative approach to streamlining trial processes represents the kind of innovation our members and partners need for more accessible clinical trials. We look forward to the Hawthorne Health team’s unique perspective to advance our global, site-focused initiatives.” For more information about the SCRS Global Impact Partner program, visit scrsprograms.com. About Hawthorne Health Hawthorne Health is the leading community site network, with 75+ locations across the U.S. and a mission to make clinical trials more accessible. Supporting 12+ therapeutic areas and partnering with more than 40 study sponsors, Hawthorne leverages intelligent technology to expand patient access, improve retention, and reduce study costs. By embedding high-quality, compliant research within local communities, Hawthorne streamlines the trial process—making it scalable, cost-effective, and patient-centric. This approach helps shorten timelines and bring better treatments to market, faster. To learn more, visit www.hawthornehealth.com. About the Society for Clinical Research Sites (SCRS) The Society for Clinical Research Sites (SCRS) is the leading advocacy organization dedicated to unifying the voice of the global clinical research site community. Representing more than 11,000 research sites in 50+ countries, SCRS facilitates industry collaborations and conversations dedicated to site-focused advocacy, education, mentorship, and connection. SCRS is an active and influential champion for sites in industry initiatives to ensure that the perspective of sites is heard and valued.  Learn more and get involved at myscrs-new.local/. Our voice. Our community. Your success.

February 25, 2025 – The Society for Clinical Research Sites (SCRS) proudly announces that Novotech, a leading contract research organization (CRO) providing comprehensive clinical trial solutions across global biotech markets, has joined the SCRS Global Impact Partner (GIP) program. By joining this esteemed network, Novotech will engage in SCRS working groups, conferences, and training opportunities designed to optimize site-CRO collaboration. With over 5,000 clinical projects completed, including Phase I to IV clinical trials and bioequivalence studies, Novotech brings extensive experience across a diverse range of therapeutic areas. The company has particular expertise in oncology/immuno-oncology, infectious diseases/vaccines, neurology, and rare diseases, and offers services such as regulatory and drug development consulting, clinical monitoring, statistical analysis, pharmacovigilance, medical advisory, and more. As a Global Impact Partner, Novotech will actively contribute to SCRS initiatives designed to enhance site sustainability, streamline study execution, and promote best practices in clinical research. Through the strategic partnership, Novotech will contribute to SCRS resources, including site engagement programs, industry insights, and leadership forums that address critical challenges in the evolving research landscape. “Becoming a part of the SCRS Global Impact Partner Program reinforces our commitment to fostering stronger collaborations between clinical research sites and Novotech globally. This partnership enhances our ability to deliver high-quality, efficient clinical trials by supporting site development, driving operational excellence, and advancing innovation in clinical research”, states Terra Johnston, Director Regulatory Operations, Novotech. “Joining the SCRS GIP Program represents Novotech’s mission to continuously enhance the quality of clinical trials, particularly through strengthening collaboration with research sites,” said Marcus Maleck, Vice President of Global Business Partnerships at SCRS. “Novotech’s extensive experience in biotech trials and dedication to site partnerships make them a valuable addition to our Global Impact Partner program. We are excited to collaborate with Novotech to advance initiatives that empower research sites and improve clinical trial execution on a global scale.” SCRS Global Impact Partners are industry leaders committed to fostering stronger site partnerships and advocating for site needs within the clinical research ecosystem. For more information about SCRS and the Global Impact Partner program, visit https://scrsprograms.com.   About Novotech Founded in 1997, Novotech is a global full-service clinical Contract Research Organization (CRO) focused on partnering with biotech companies to accelerate the development of advanced and novel therapeutics at every phase. Recognized for its industry-leading contributions, Novotech has received numerous prestigious awards, including the Frost & Sullivan 2024 Global Biotech CRO Award, 2024 Clinical Trials Arena Award for Excellence in Business Expansion, Marketing, and Innovation,  2024 Employer of Choice, 2024 Great Place to Work in the US, 2024 Brandon Hall Gold Award, CRO Leadership Award 2023, the Asia Pacific Cell & Gene Therapy Clinical Trials Excellence 2023, the Asia-Pacific Contract Research Organization Company of the Year Award since 2006. The Company offers a comprehensive suite of services including laboratories, Phase I facilities, drug development consulting, regulatory expertise, and has experience with over 5,000 clinical projects, including Phase I to Phase IV clinical trials and bioequivalence studies. With a presence in 34 office locations and a dedicated team of 3,000+ professionals worldwide, Novotech is a trusted end-to-end strategic partner of choice. For more information or to speak to an expert team member visit www.Novotech-CRO.com   About the Society for Clinical Research Sites (SCRS)  The Society for Clinical Research Sites (SCRS) is the leading advocacy organization dedicated to unifying the voice of the global clinical research site community. Representing more than 11,000 research sites in 50+ countries, SCRS facilitates industry collaborations and conversations dedicated to site-focused advocacy, education, mentorship, and connection. SCRS is an active and influential champion for sites in industry initiatives to ensure that the perspective of sites is heard and valued. Learn more and get involved at myscrs.org. Our voice. Our community. Your success.  

Fortrea to Sponsor SCRS’ Collaborate Forward Working Group, Encouraging Collaboration for More Efficient Clinical Trials February 20, 2025 – The Society for Clinical Research Sites (SCRS) and Fortrea (Nasdaq: FTRE), a leading global contract research organization (CRO), are pleased to announce Fortrea’s sponsorship of the SCRS Collaborate Forward working group. Comprising 16 leading Global Impact Partner organizations, the Collaborate Forward working group will explore and develop best practices to reduce administrative burdens across the clinical research ecosystem. The group is committed to fostering transparency and collaboration to tackle challenges faced by clinical research sites. By improving internal processes, they aim to make sites more sustainable and trials more efficient—ultimately leading to a smoother experience for patients. Fortrea’s sponsorship marks a significant investment in fostering industry-wide innovation and reflects the company’s dedication to placing sites at the forefront of clinical trial planning. “We are excited to partner with SCRS to launch and support this working group,” said Mike Clay, Senior Vice President of Global Project Delivery at Fortrea. “Clinical trials are becoming increasingly complex, and the industry faces mounting pressure to accelerate innovation for patients. We believe that collaboration with clinical research sites is key to unlocking efficiencies and productivity gains that will streamline the clinical trial process. This initiative will develop tangible solutions that clinical study sponsors, CROs, vendors, sites, and patient advocacy groups can rally behind. As a leading CRO, we are proud to be at the forefront of this effort, ensuring that sites remain central to driving progress and fostering greater industry-wide collaboration to bring life-changing treatments to patients faster.” “Clinical research requires a unique interdependency to generate the best outcomes. Collaborate Forward will share partnership successes that impact the people, process, and technology improving clinical research today,” added Sean Soth, Senior Vice President, Strategy and Global Business Partnerships, SCRS. “We are pleased to welcome Fortrea as the charter sponsor of Collaborate Forward. This partnership underscores the value of cross-industry collaboration and the collective effort needed to drive meaningful progress in creating a more connected and efficient clinical trial ecosystem.” Collaborate Forward will initially focus on study startup, showcasing the advantages of collaboration through compelling stories, case studies, and data-driven insights. The group will convene regularly to exchange insights, assess industry trends, and develop pragmatic tools that sponsors and CROs can implement within their organizations. Updates on the working group’s progress will be shared throughout 2025 via SCRS Site Solutions Summits and publications, highlighting key findings and collaborative achievements. SCRS invites sponsors and CROs committed to site sustainability to join this effort and contribute to shaping a more effective and synergistic clinical research landscape. For more information on how to participate, please contact Brian Egan. About The Society for Clinical Research Sites (SCRS) The Society for Clinical Research Sites (SCRS) is the leading advocacy organization dedicated to unifying the voice of the global clinical research site community. Representing more than 11,000 research sites globally, SCRS facilitates industry collaborations and conversations dedicated to site-focused advocacy, education, mentorship, and connection. SCRS is an active and influential champion for sites in industry initiatives to ensure that the perspective of sites is heard and valued. Learn more and get involved at myscrs-new.local/. Our voice. Our community. Your success. About Fortrea Fortrea (Nasdaq: FTRE) is a leading global provider of clinical development solutions to the life sciences industry. We partner with emerging and large biopharmaceutical, biotechnology, medical device and diagnostic companies to drive healthcare innovation that accelerates life changing therapies to patients. Fortrea provides phase I-IV clinical trial management, clinical pharmacology and consulting services. Fortrea’s solutions leverage three decades of experience spanning more than 20 therapeutic areas, a passion for scientific rigor, exceptional insights and a strong investigator site network. Our talented and diverse team working in about 100 countries is scaled to deliver focused and agile solutions to customers globally. Learn more about how Fortrea is becoming a transformative force from pipeline to patient at Fortrea.com and follow us on LinkedIn and X (formerly Twitter). SCRS Contacts: Marissa Hill (Media) – 267-865-3296, marissa.hill@myscrs.org Brian Egan (Media) – 518-207-6965, brianeegan@gmail.com Fortrea Contacts: Galen Wilson (Media) – 703-298-0802, media@fortrea.com Kate Dillon (Media) – 646-818-9115, kdillon@prosek.com

February 19, 2025 – The Society for Clinical Research Sites (SCRS) announced today that Verdiva Bio, a clinical-stage biotechnology company focused on developing innovative therapies for obesity and other cardiometabolic disorders, has joined the SCRS Global Impact Partner (GIP) program. As the first biotechnology company to join the program, Verdiva Bio will bring a unique perspective to the group of more than 70 research sites, CROs, and pharmaceutical sponsors. Verdiva Bio’s pipeline includes a potential first-in-class once weekly oral amylin agonist, a potential best-in-class subcutaneous amylin agonist, and a Phase 2 ready, potential first-in-class, once weekly oral GLP-1 receptor agonist, along with other undisclosed programs. Verdiva plans to advance the development of these next-generation therapeutic candidates via a mix of monotherapy and combination programs with the goal of providing more patient-friendly therapeutic options to people living with obesity, cardiometabolic disorders, and related complications. “We are proud to be a SCRS Global Impact Partner, where we have the opportunity to deepen our understanding of the needs of clinical trial sites and aim to deliver patient-centric solutions for clinical research.  We look forward to working closely with our site partners and understanding what they need for success, so we can aim to optimize trial processes to accelerate the development of our product candidates,” said Chris Clevenger, SVP Clinical Operations & Medical Affairs at Verdiva Bio. “SCRS is thrilled to welcome Verdiva Bio as the first biotechnology company to join the SCRS Global Impact Partner program,” said Marcus Maleck, Vice President of Global Business Partnerships at SCRS. “Their expertise in obesity and cardiometabolic research brings a valuable perspective to our community of sites, CROs, sponsors and service providers. We look forward to collaborating on solutions that support research site success and industry partnerships.” As a GIP, Verdiva Bio will contribute to SCRS initiatives, working groups, and advisory boards, gaining valuable insights into site operations while sharing expertise in patient recruitment, budgeting, and operational strategy. The partnership provides Verdiva Bio with direct engagement opportunities across SCRS’s global network of research sites, allowing for collaboration on critical site challenges and trial efficiencies. Learn more about SCRS Global Impact Partners at myscrs-new.local/industry-partnerships/global-impact-partners. About Verdiva Bio Verdiva Bio is committed to developing next-generation therapies to help people living with obesity, cardiometabolic disorders, and related complications achieve better outcomes via more patient-friendly therapeutic options. Verdiva’s most advanced therapy is VRB-101, an oral GLP-1 peptide in clinical development that has demonstrated potential for best-in-class efficacy and once-weekly dosing in a phase 1 study in Australia. The Company is also developing a portfolio of amylin molecules, including oral and subcutaneous agonists, and other undisclosed programs that, if successful, may offer the potential for enhanced efficacy, improved tolerability, and healthier weight loss. The Verdiva team harnesses the emerging science in gut-brain biology and leverages their history of successful drug development to advance novel therapeutic candidates aiming to transform the lives of millions living with obesity worldwide. For more information, please visit www.verdivabio.com. About the Society for Clinical Research Sites (SCRS)  The Society for Clinical Research Sites (SCRS) is the leading advocacy organization dedicated to unifying the voice of the global clinical research site community. Representing more than 11,000 research sites in 50+ countries, SCRS facilitates industry collaborations and conversations dedicated to site-focused advocacy, education, mentorship, and connection. SCRS is an active and influential champion for sites in industry initiatives to ensure that the perspective of sites is heard and valued. Learn more and get involved at myscrs-new.local/. Our voice. Our community. Your success.  

December 3, 2024 – The Society for Clinical Research Sites (SCRS) is proud to announce Scout as a new Global Impact Partner (GIP). Scout is a leader in services and technology for the biopharmaceutical industry, offering globally-compliant services that simplify complex logistics for pharmaceutical and biotech leaders in 109 countries. Established as a one-bedroom operation in 1995, Scout has since grown to emerge as a global leader in the clinical services space. The organization is committed to relieving site and patient burden throughout the clinical research process. Their award-winning Scout Portal offers flexible reimbursement options through ScoutPass®, electronic funds transfer, and other methods to ensure patient needs are met seamlessly at no expense to sites. Through the SCRS Global Impact Partner program, Scout will collaborate closely with SCRS and its network of over 10,000 research sites worldwide, contributing to SCRS initiatives and participating in discussions that shape the future of the research industry. This partnership highlights Scout’s dedication to streamlining clinical trials through site-focused solutions that support patient retention, improve trial logistics, and strengthen cross-industry collaboration. “In joining with SCRS as a Global Impact Partner, Scout reaffirms our dedication to advancing clinical research through strategic collaboration,” stated Moisha Platto, CEO of Scout. “We’re looking forward to elevating our support for research sites and patients globally through this partnership.”  “With Scout joining as a Global Impact Partner, SCRS gains a collaborator who shares our commitment to advancing clinical research site support and patient-centered trials,” said Marcus Maleck, Vice President of Global Business Partnerships at SCRS. “Scout’s expertise in streamlining patient logistics and delivering comprehensive training resources resonates with our mission to empower research sites. Together, we look forward to creating meaningful advancements in site support and patient engagement that will strengthen clinical trials globally.” About Scout Scout empowers the life sciences industry with people-first solutions: Scout Meetings, Scout Clinical, and Scout Academy. We specialize in face-to-face, virtual, and hybrid clinical meeting planning, patient payment, travel, and logistics support, and virtual collaboration and education. Since 1995, we’ve been a trusted partner in customer service, regulatory compliance, and project delivery for leading pharmaceutical and biotechnology companies. Our deep understanding of international regulations and adaptable network of resources is built on operational experience in 109 countries. With white-glove attention to detail and a customizable, comprehensive range of services, Scout makes the complex easier. Visit scoutclinical.com.  About the Society for Clinical Research Sites (SCRS)  The Society for Clinical Research Sites (SCRS) is the leading advocacy organization dedicated to unifying the voice of the global clinical research site community. Representing more than 11,000 research sites globally, SCRS facilitates industry collaborations and conversations dedicated to site-focused advocacy, education, mentorship, and connection. SCRS is an active and influential champion for sites in industry initiatives to ensure that the perspective of sites is heard and valued. Learn more and get involved at myscrs-new.local/. Our voice. Our community. Your success. 

October 10, 2024  – The Society for Clinical Research Sites (SCRS) is proud to announce William Smith, MD, as the recipient of the 2024 Christine K. Pierre Site Impact Award. The Christine K. Pierre Site Impact Award recognizes an industry leader who has made an extraordinary contribution to furthering the voice of the clinical research site community. Dr. William B. Smith, CEO and Principal Investigator of AMR (Alliance for Multispecialty Research), has conducted over 2,000 clinical trials across phases I-IV in his 40+ year career. He has been actively involved in SCRS since its inception, serving on the Leadership Council, Global Site Solutions Summit planning committee, and Workforce Task Force. A key part of Dr. Smith’s work focuses on site sustainability by engaging and training new physicians in clinical research. “To receive an award with Christine Pierre’s name on it is particularly special,” said Dr. Smith. “Christine and I shared the same vision to empower clinical research sites and give sites an avenue to collaborate, share and plan for sustainability. I have received awards and accolades during my 40+ year career in clinical research, but none have touched me as deeply as this award has.” Allyson Small, SCRS Chief Operating Officer, added, “Dr. William Smith has been a steadfast advocate for SCRS and the clinical research site community throughout his career. He shared a vision with SCRS founder Christine Pierre for sites to unite and collaborate for greater impact and influence industry decisions. In line with the core pillars of SCRS—advocacy, education, connection, and mentorship—he is highly deserving of an award that honors Christine Pierre’s legacy. SCRS is proud to recognize Dr. Smith for his unwavering passion for the clinical research site community and improving the lives of patients worldwide.” Award nominations were open to any individuals employed by an SCRS member research site. For more information on the Christine K. Pierre Site Impact Award, visit the Global Site Solutions Summit website at sitesolutionssummit.com. About the Society for Clinical Research Sites (SCRS)  The Society for Clinical Research Sites (SCRS) is the leading advocacy organization dedicated to unifying the voice of the global clinical research site community. Representing more than 11,000 research sites in 54 countries, SCRS facilitates industry collaborations and conversations dedicated to site-focused advocacy, education, mentorship, and connection. SCRS is an active and influential champion for sites in industry initiatives to ensure that the perspective of sites is heard and valued. Learn more and get involved at myscrs-new.local/. Our voice. Our community. Your success. 

October 9, 2024 — The Society for Clinical Research Sites (SCRS) is pleased to announce that FOMAT Medical Research has been named the recipient of the 2024 Excellence in Patient Centricity Award. Sponsored by Sanofi, this award celebrates a clinical research site that consistently prioritizes patient experience in its operations. FOMAT Medical Research distinguished itself through its innovative approach to patient recruitment and engagement, utilizing advanced artificial intelligence (AI) technologies. Their AI-driven tools, including an immediate engagement platform and the virtual assistant “Lucy,” have transformed how they interact with study participants. Lucy ensures that no call goes unanswered, giving participants a sense of being heard and valued from their first contact. Additionally, FOMAT’s use of AI-powered voiceovers in social media ads simplifies complex clinical trial information, making it more accessible and appealing to diverse patient populations. Nicholas Focil, CEO of FOMAT, commented, “We are honored to be recognized by SCRS and even more so for their Excellence in Patient Centricity Award. This award and what it stands for, is the highest honor for us here at FOMAT It’s a reflection of our team’s unwavering dedication of always having the patients front and center. At FOMAT, we believe that innovation and technology are key to addressing the evolving needs of our patients and providing them with the best possible care throughout their research journey.” “The Excellence in Patient Centricity Award celebrates those sites that put patients first, and FOMAT Medical Research’s innovative approach to patient-centricity is truly exceptional,” said Jimmy Bechtel, SCRS Vice President of Site Engagement. “Their use of AI to bridge the gap between patients and research sites sets a new standard in the industry. SCRS applauds their commitment to improving the clinical trial experience and ensuring that patients are engaged, respected, and prioritized at every step.” Vicky DiBiaso, Head of Patient Informed Development & Health Value Translation, added, “Sanofi is proud to sponsor the 4th annual SCRS Excellence in Patient Centricity Award. We are deeply appreciative of the contributions all trial sites make to the advancement of medical treatments. Through this award, we are honored to celebrate FOMAT and their digital innovations making clinical research an accessible and positive experience for both patient and caregiver communities!” 2024 Excellence in Patient Centricity Award finalists included EMS Healthcare, FOMAT Medical Research, IMA Clinical Research, and Velocity Clinical Research. For more information about the Excellence in Patient Centricity Award, visit the Global Site Solutions Summit website. About the Society for Clinical Research Sites (SCRS) The Society for Clinical Research Sites (SCRS) is the leading advocacy organization dedicated to unifying the voice of the global clinical research site community. Representing more than 11,000 research sites in 54 countries, SCRS facilitates industry collaborations and conversations dedicated to site-focused advocacy, education, mentorship, and connection. SCRS is an active and influential champion for sites in industry initiatives to ensure that the perspective of sites is heard and valued. Learn more and get involved at myscrs-new.local/. Our voice. Our community. Your success.